Subantimicrobial Doxycycline in Acne

Completed · Phase 4

Conditions studied: Acne Vulgaris, Pediatrics

In brief

Antibiotic resistance is a public health problem that worsens the more physicians prescribe standard dose antibiotics for acne. Regardless of race, acne vulgaris is one of the most common dermatologic conditions among pediatric populations. As such, clinicians can make a large impact by practicing good antibiotic stewardship while still addressing the impact of acne on adolescents' self-esteem. Subantimicrobial doxycycline maintains its anti-inflammatory effects while eliminating antimicrobial properties and associated risks of drug resistance. Few studies, focused primarily on adults, have shown that subantimicrobial doxycycline is efficacious in treating acne from a physician standpoint. The investigators aim to investigate the patient experience of acne treatment with subantimicrobial dose doxycycline in the pediatric population.

Key facts

Study ID

NCT05399290

Run by

Michigan State University

People needed

22

Starts

2020-11-19

Expected to finish

2021-11-08

Last updated by the study team

2023-04-03

Who can join

Age: 13 and older, up to 17. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Documented moderate to severe facial acne

You may not qualify if…

• Other skin conditions on the face
• Previous antibiotic treatment for acne
• Use of antibiotics for any reason within the past month
• Use of new prescription regiment for acne within the last 3 months
• Positive pregnancy test in the clinic
• Cognitive impairments

Where it is running

• Messenger Dermatology Clinic — Lansing, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.